FDMT Q2 2023 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$239,000+47.5% YoY

Gross Profit

-$23M-9767.8% margin

Operating Income

-$32M-13446.0% margin

Net Income

-$30M-12391.6% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

-19.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$353M

Total Liabilities

$27M

Stockholders' Equity

$325M

Cash & Equivalents

$236M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$239,000	$162,000	+47.5%
Gross Profit	-$23M	-$20M	-15.2%
Operating Income	-$32M	-$28M	-13.1%
Net Income	-$30M	-$28M	-5.4%

Geographic Segments

NETHERLANDS

$230,00096%

UNITED STATES

$9,0004%